Disc Medicine (IRON) Notes Payables (2020 - 2021)
Disc Medicine (IRON) posted quarterly Notes Payables of $6.4 million for Q4 2021, down 44.82% year-over-year from $11.7 million in Q4 2020, and down 44.82% quarter-over-quarter from $11.7 million in Q4 2020.
Powered by 
Analysis
Disc Medicine (IRON) Notes Payables (2020 - 2021) Analysis & Trends
Disc Medicine (IRON) has reported Notes Payables for 2 consecutive years, with $6.4 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Notes Payables fell 44.82% year-over-year to $6.4 million; the TTM figure through Dec 2021 stood at $6.4 million (down 44.82% YoY), while the FY2021 annual figure was $6.4 million, down 44.82% from the prior year.
- Notes Payables fell to $6.4 million in Q4 2021 per IRON's latest filing, from $11.7 million in the prior quarter.
- Across five years, Notes Payables topped out at $11.7 million in Q4 2020 and bottomed at $6.4 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - |